Rosavin

Rosavin, an orally bioactive phenylpropanoid from Rhodiola rosea L. (RRL), is an adaptogen that enhances the body’s response to environmental stress. Rosavin significantly influences bone tissue metabolism by inhibiting osteoclastogenesis and promoting osteoblast differentiation, also impacts various diseases, demonstrating antidepressant, adaptogenic, and anxiolytic effects in mouse models. Additionally, Rosavin improves survival, reducing intestinal damage in irradiated rats and Ischemia-reperfusion(I/R)-induced cerebral injury in vivo by regulating inflammation and oxidative stress, making it a promising candidate for research in radiation-induced intestinal injury, I/R-induced cerebral injury and osteoporosis[1][2][3][4].

[1]Weijie Zhou, et al. The Protective Effect of Rosavin from Rhodiola rosea on Radiation-Induced Intestinal Injury[J]. Chem. Biodiversity. 2020 October 22, 17, e2000652.|[2]Liu QH, et al. Rosavin Alleviates LPS-Induced Acute Lung Injure by Modulating the TLR-4/NF-κB/MAPK Singnaling Pathways[J]. Int J Mol Sci. 2024 Feb 3;25(3):1875. |[3]Zou H, et al. Rosavin protects the blood-brain barrier against ischemia/reperfusion-induced cerebral injury by regulating MAPK-mediated MMPs pathway[J]. Clin Exp Pharmacol Physiol. 2023 Aug;50(8):664-676.|[4]Wojdasiewicz P, et al. The Role of Rosavin in the Pathophysiology of Bone Metabolism[J]. Int J Mol Sci. 2024 Feb 9;25(4):2117.